-
PTC Therapeutics to Participate at Upcoming Investor Conferences
-
Citi Reiterates Sell Rating on PTC Therapeutics (PTCT)
-
Citi Reiterates Sell Rating on PTC Therapeutics (PTCT), 'PIVOT-HD Data Update Supportive, But Expectations Measured to this Point'
-
Citi Downgrades PTC Therapeutics (PTCT) to Sell, 'Regulatory Headwinds Compound'
-
PTC Therapeutics to Participate at Upcoming Investor Conferences
-
PTC Therapeutics (PTCT) PT Raised to $70 at Citi, 'Post-data, we increased our sepiapterin POS to 90%'
-
UPDATE: Citi Upgrades PTC Therapeutics (PTCT) to Buy
-
Citi Downgrades PTC Therapeutics (PTCT) to Neutral
-
UPDATE: Citi Downgrades PTC Therapeutics (PTCT) to Neutral
-
PTC Therapeutics (PTCT) Reiterated Buy at Citi Ahead of Risdiplam Data
-
PTC Therapeutics (PTCT) PT Raised to $62 at Citi
-
Pre-Open Movers 06/28: (CDMO) (CAMP) (PRGS) (LJPC) (STZ) (BAC) (SRNE) (more...)
-
PTC Therapeutics (PTCT) PT Lowered to $59 at Citi
-
PTC Therapeutics (PTCT) PT Lowered to $59 at Citi
-
PTC Therapeutics (PTCT) PT Raised to $50 at Citi
-
PTC Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
-
PTC Therapeutics (PTCT) Prices 4M Share Offering at $27.04/Sh
-
PTC Therapeutics Announces Pricing of Public Offering of Common Stock
-
PTC Therapeutics (PTCT) Commences 4M Share Offering of Common Stock
-
PTC Therapeutics Announces Proposed Public Offering of Common Stock
-
Pre-Open Movers 10/09: (CLNT) (TROV) (GEVO) Higher; (XXII) (KTWO) (PTCT) Lower (more...)
-
PTC Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
-
PTC Therapeutics (PTCT) PT Raised to $28 at Citi; Sees $20 Upside If Translarna is Approved
-
PTC Therapeutics (PTCT) PT Raised to $18 at Citi, Worth $59/Share If Translama Is Approved Or $8/Share If Rejected
-
Notable Analyst Rating Changes 11/14: (SQ) (PTCT) (CLF) Upgraded; (STI) (STLD) (RARE) Downgraded
-
Unusual 11 Mid-Day Movers 11/11: (PTCT) (AWX) (CXRX) Higher; (PLAB) (EMAN) (HMY) Lower
-
Citi Downgrades PTC Therapeutics (PTCT) to Neutral
-
Pre-Open Stock Movers 02/23: (NEWP) (MMSI) (TXRH) Higher; (PTCT) (FIT) (WDC) Lower (more...)
-
Notable Analyst Rating Changes 11/25: (PFE) (IMGN) (PANW) Upgraded; (SUNE) (PTCT) (TIF) Downgraded
-
Notable Analyst Rating Changes 8/25: (AAPL) (BAC) (RF) Upgraded; (BOKF) (SUNE) (GAS) Downgraded
-
UPDATE: PTC Therapeutics (PTCT) Risk/Reward Seen as Favorable, Citi Starts at Buy
-
PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update
-
Pre-Open Stock Movers 04/23: (ARRS) (DNKN) (SKX) Higher; (MOBL) (MTH) (TXN) Lower (more...)
-
Notable Analyst Rating Changes 4/16: (COH) (INTC) (LOW) Upgraded; (AGCO) (NOK) (TRQ) Downgraded
-
Citi Starts PTC Therapeutics (PTCT) at Buy
-
PTC Therapeutics (PTCT) Prices 3M Common Offering at $36.25/Share
-
PTC Therapeutics (PTCT) Announces 3M Common Stock Offering
-
Notable Analyst Rating Changes 07/15: (LEAP) (DECK) (TIF) Upgraded; (VVUS) (UPS) (QLGC) Downgraded

